Opna Bio's OPN-6602, an oral EP300/CBP bromodomain inhibitor, receives FDA orphan drug designation for relapsed/refractory multiple myeloma based on Phase 1 trial results.
Opna Bio has dosed the first subject in a Phase I clinical trial of OPN-6602, an EP300/CBP bromodomain inhibitor, for relapsed or refractory multiple myeloma.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.